JP5653945B2 - 抗ｃｄ４０抗体及びその使用 - Google Patents

抗ｃｄ４０抗体及びその使用 Download PDF

Info

Publication number
JP5653945B2
JP5653945B2 JP2011554097A JP2011554097A JP5653945B2 JP 5653945 B2 JP5653945 B2 JP 5653945B2 JP 2011554097 A JP2011554097 A JP 2011554097A JP 2011554097 A JP2011554097 A JP 2011554097A JP 5653945 B2 JP5653945 B2 JP 5653945B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
cells
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011554097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520074A (ja
Inventor
ジャック エフ． バンチェレイア
ジャック エフ． バンチェレイア
ジェラルド ズラウスキ
ジェラルド ズラウスキ
サンドラ ズラウスキ
サンドラ ズラウスキ
サンコン オー
サンコン オー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Research Institute
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of JP2012520074A publication Critical patent/JP2012520074A/ja
Application granted granted Critical
Publication of JP5653945B2 publication Critical patent/JP5653945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
JP2011554097A 2009-03-10 2010-03-05 抗ｃｄ４０抗体及びその使用 Active JP5653945B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US15905909P 2009-03-10 2009-03-10
US15905509P 2009-03-10 2009-03-10
US15906209P 2009-03-10 2009-03-10
US61/159,055 2009-03-10
US61/159,062 2009-03-10
US61/159,059 2009-03-10
US12/718,365 US9562104B2 (en) 2009-03-10 2010-03-05 Anti-CD40 antibodies
US12/718,365 2010-03-05
PCT/US2010/026375 WO2010104761A2 (en) 2009-03-10 2010-03-05 Anti-cd40 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014157365A Division JP6329842B2 (ja) 2009-03-10 2014-08-01 抗ｃｄ４０抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2012520074A JP2012520074A (ja) 2012-09-06
JP5653945B2 true JP5653945B2 (ja) 2015-01-14

Family

ID=42729029

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011554097A Active JP5653945B2 (ja) 2009-03-10 2010-03-05 抗ｃｄ４０抗体及びその使用
JP2014157365A Active JP6329842B2 (ja) 2009-03-10 2014-08-01 抗ｃｄ４０抗体及びその使用
JP2016198376A Ceased JP2017061463A (ja) 2009-03-10 2016-10-06 抗ｃｄ４０抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014157365A Active JP6329842B2 (ja) 2009-03-10 2014-08-01 抗ｃｄ４０抗体及びその使用
JP2016198376A Ceased JP2017061463A (ja) 2009-03-10 2016-10-06 抗ｃｄ４０抗体及びその使用

Country Status (14)

Country Link
US (6) US9562104B2 (enExample)
EP (1) EP2406286B1 (enExample)
JP (3) JP5653945B2 (enExample)
CN (2) CN102448989B (enExample)
AR (1) AR076106A1 (enExample)
AU (1) AU2010222942B2 (enExample)
BR (1) BRPI1009455A2 (enExample)
CA (2) CA2754862C (enExample)
DK (1) DK2406286T3 (enExample)
ES (1) ES2584956T3 (enExample)
MX (1) MX2011009438A (enExample)
PT (1) PT2406286T (enExample)
TW (1) TWI571264B (enExample)
WO (1) WO2010104761A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016006078A (ja) * 2009-03-10 2016-01-14 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗原提示細胞ターゲティング抗ウイルスワクチン

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10293040B1 (en) * 2006-11-06 2019-05-21 Microvax, Llc Pharmaceutical compositions and methods of blocking Bacillus anthracis
CN105837691B (zh) * 2009-03-10 2021-06-29 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
ES2584956T3 (es) 2009-03-10 2016-09-30 Baylor Research Institute Anticuerpos anti-CD40 y usos de los mismos
GB201006096D0 (en) * 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
WO2011137245A2 (en) 2010-04-30 2011-11-03 Esperance Pharmaceuticals, Inc. Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108117586A (zh) 2010-08-10 2018-06-05 洛桑聚合联合学院 红细胞结合性治疗剂
AR082686A1 (es) * 2010-08-13 2012-12-26 Baylor Res Inst Adyuvantes de vacuna que direccionan a los adyuvantes de anticuerpos directamente hacia las celulas presentadoras de antigenos
US20120231023A1 (en) * 2011-03-08 2012-09-13 Baylor Research Institute Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells
PL2683406T3 (pl) 2011-03-11 2019-11-29 Beth Israel Deaconess Medical Ct Inc Przeciwciała anty-cd40 i ich zastosowania
CA2831294A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
CN106928362B (zh) 2011-04-29 2021-10-26 埃派斯进有限公司 抗-cd40抗体及其使用方法
CA2857645A1 (en) 2011-11-30 2013-06-06 Wellstat Diagnostics, Llc Assays, antibodies, immunogens and compositions related to 5-fu
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
US20160296609A1 (en) 2013-06-28 2016-10-13 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
CN120939216A (zh) 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
EA201691686A1 (ru) 2014-02-21 2017-03-31 Эколь Политекник Федераль Де Лозан (Эпфл) Терапевтические средства с углевод-опосредованной адресной доставкой
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
BR112016028418A2 (pt) * 2014-06-05 2018-02-20 Univ Arkansas composição de adjuvante, vacina, anticorpo agonista cd40 ou uma parte desse, composição farmacêutica, construto, célula, e, método de mapeamento de epítopo de um polipeptídeo
WO2015196180A2 (en) * 2014-06-20 2015-12-23 Gillies Stephen D Influenza vaccines and methods of use thereof
HUE048284T2 (hu) * 2015-05-29 2020-07-28 Abbvie Inc Anti-CD40 antitestek és alkalmazásuk
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
EP3632933A4 (en) * 2017-06-01 2021-03-03 Seoul National University R & DB Foundation Novel anti-cd40 antibodies and use thereof
CN110267989B (zh) * 2017-06-01 2023-04-04 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CN109384848A (zh) * 2017-08-10 2019-02-26 深圳市雅臣智能生物工程有限公司 抗人乳头瘤病毒和抗cd人源化的双靶向抗体及其组合物、制备方法和应用
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
EP3823987A4 (en) * 2018-07-20 2022-03-02 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof
US20220175920A1 (en) * 2019-03-27 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
MX2022007688A (es) * 2019-12-20 2022-07-19 Amgen Inc Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
CN116262783A (zh) * 2021-12-14 2023-06-16 中国科学院深圳先进技术研究院 胚胎干细胞来源的肿瘤抗原表位肽及其应用
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4012A (en) * 1845-04-26 Improvement in electrographic printing
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
CA2129514A1 (en) 1992-03-12 1993-09-16 M. Amin Khan Controlled released acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
DE4233152A1 (de) 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
EP0679187B2 (de) 1993-01-16 2001-07-04 SCHAWALLER, Manfred Verfahren zur gewinnung nativer, oligomerer, glykosylierter ektodomänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US6040137A (en) 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
EP1033406A4 (en) 1997-10-27 2005-03-09 Sumitomo Electric Industries INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
CZ302870B6 (cs) 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
AU760669B2 (en) 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
EP1246643A4 (en) 1999-10-14 2005-05-11 Jeffery A Ledbetter DNA VACCINES ENCODING ANTIGEN ASSOCIATED WITH CD40-BINDING DOMAIN
GB9926084D0 (en) 1999-11-03 2000-01-12 King S College London Recombinant fusion molecules
US7371392B2 (en) 2000-02-02 2008-05-13 The United States Of America As Represented By The Department Of Health And Human Services Cd40 ligand adjuvant for respiratory syncytial virus
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
AU6138301A (en) 2000-05-08 2001-11-20 Medarex Inc Human monoclonal antibodies to dendritic cells
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US20030232055A1 (en) 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
DE60143535D1 (de) * 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
JP4025881B2 (ja) 2001-04-27 2007-12-26 キリンファーマ株式会社 抗ｃｄ４０モノクローナル抗体
PT1391464E (pt) 2001-04-27 2007-11-15 Kirin Pharma Kk Anticorpo monoclonal anti-cd40
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
WO2003029296A1 (en) 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
FR2837104B1 (fr) 2002-03-14 2004-08-06 Dev Des Antigenes Combinatoire Utilisation de melange de lipopeptides pour la fabrication de vaccins
US7456260B2 (en) 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
CN100381463C (zh) 2002-09-18 2008-04-16 中国人民解放军免疫学研究所 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途
US20040146948A1 (en) 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
JP2004192125A (ja) 2002-12-09 2004-07-08 Mitsue-Links Co Ltd プロジェクトマネジメントシステム及びそれに用いられるデータ構造、並びに、プロジェクトマネジメント方法
GB0228796D0 (en) 2002-12-11 2003-01-15 Adjuvantix Ltd Valency
CN1747970A (zh) 2003-02-06 2006-03-15 三肽公司 抗原/抗体或配体/受体糖基化的特异性交换剂
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
DK1707627T3 (da) 2003-12-25 2012-12-17 Kyowa Hakko Kirin Co Ltd Antagonistisk anti-CD40-antistofmutant.
EP1765870A2 (en) * 2004-06-03 2007-03-28 Medarex, Inc. Human monoclonal antibodies to fc gamma receptor i (cd64)
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
JP5027804B2 (ja) * 2005-05-26 2012-09-19 シアトル ジェネティクス，インコーポレーテッド ヒト化抗ｃｄ４０抗体およびその使用方法
JP2007026135A (ja) 2005-07-19 2007-02-01 Shimizu Corp プログラムマネジメントチャート作成支援システム
US7608272B2 (en) 2005-08-30 2009-10-27 Board Of Regents Of The University Of Nebraska Methods and compositions for vaccination of animals with PRRSV antigens with improved immunogenicity
EP1948802A4 (en) 2005-10-13 2009-01-14 Virexx Medical Corp CHIMERIC ANTIGEN WITH HEPATITIS C VIRUS POLYPEPTIDE AND FC FRAGMENT FOR CALLING UP AN IMMUNE RESPONSE
US20080286289A1 (en) * 2005-10-28 2008-11-20 Cynthia Duchala Use of B Cell Expansion Agents in Generating Antibodies
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US7993648B2 (en) 2006-05-03 2011-08-09 The Regents of the Universitry of Colorado Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
US7804955B2 (en) 2006-06-21 2010-09-28 Sony Ericsson Mobile Communications Ab Flexible key plate
AU2007312367B2 (en) 2006-10-12 2012-09-06 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-EREG antibody
US20080241139A1 (en) 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
MX2009008140A (es) 2007-02-02 2009-10-26 Baylor Res Inst Vacunas a base de antigeno dirigido a dcir expresado en celulas que presentan antigeno.
WO2008097817A2 (en) 2007-02-02 2008-08-14 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
EP2160401B1 (en) 2007-05-11 2014-09-24 Altor BioScience Corporation Fusion molecules and il-15 variants
US20090023822A1 (en) * 2007-07-19 2009-01-22 Tijm Peter J Method for activating and regenerating catalyst for a fischer-tropsch synthesis reaction
JP5233505B2 (ja) 2008-03-17 2013-07-10 株式会社リコー 共同作業支援装置、共同作業支援システム、共同作業支援方法、プログラムおよび記録媒体
JP5984388B2 (ja) * 2008-07-16 2016-09-06 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン
ES2584956T3 (es) * 2009-03-10 2016-09-30 Baylor Research Institute Anticuerpos anti-CD40 y usos de los mismos
DK2406288T3 (en) 2009-03-10 2017-03-27 Baylor Res Inst ANTIGEN PRESENTING CELL-TARGETED VACCINES
CN105837691B (zh) 2009-03-10 2021-06-29 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
JP2013503140A (ja) * 2009-08-27 2013-01-31 ノヴォ ノルディスク アー／エス 活性化血小板に対する組織因子の標的化
AR078423A1 (es) 2009-09-14 2011-11-09 Baylor Res Inst Vacunas dirigidas a las celulas de langerhans
CN103153338A (zh) 2010-05-07 2013-06-12 贝勒研究院 树突细胞免疫受体（dcir）介导的人类cd8+t细胞的交叉敏化
JP2012052007A (ja) 2010-08-31 2012-03-15 Fujifilm Corp 環状リンカーボネート化合物、難燃剤、樹脂組成物、及び電気電子機器用筐体
WO2012129227A1 (en) 2011-03-22 2012-09-27 Baylor Research Institute Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
JP2014157365A (ja) * 2014-04-30 2014-08-28 Canon Inc 電子写真画像形成装置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016006078A (ja) * 2009-03-10 2016-01-14 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗原提示細胞ターゲティング抗ウイルスワクチン

Also Published As

Publication number Publication date
MX2011009438A (es) 2012-04-02
TWI571264B (zh) 2017-02-21
TW201100099A (en) 2011-01-01
US10087256B2 (en) 2018-10-02
EP2406286A2 (en) 2012-01-18
AU2010222942B2 (en) 2013-01-10
DK2406286T3 (en) 2016-08-22
US11267895B2 (en) 2022-03-08
US20210024641A1 (en) 2021-01-28
US10683361B2 (en) 2020-06-16
CA3032548A1 (en) 2010-09-16
US20190085088A1 (en) 2019-03-21
JP2015028021A (ja) 2015-02-12
JP2012520074A (ja) 2012-09-06
EP2406286A4 (en) 2013-05-29
CN102448989A (zh) 2012-05-09
AU2010222942A1 (en) 2011-10-06
CN106432493A (zh) 2017-02-22
CA3032548C (en) 2023-05-09
HK1168117A1 (zh) 2012-12-21
CA2754862C (en) 2019-04-02
US20140234344A1 (en) 2014-08-21
JP6329842B2 (ja) 2018-05-23
US20100239575A1 (en) 2010-09-23
PT2406286T (pt) 2016-08-19
US20170114142A1 (en) 2017-04-27
US9562104B2 (en) 2017-02-07
AR076106A1 (es) 2011-05-18
US9567401B2 (en) 2017-02-14
JP2017061463A (ja) 2017-03-30
CA2754862A1 (en) 2010-09-16
CN102448989B (zh) 2015-09-30
EP2406286B1 (en) 2016-05-18
BRPI1009455A2 (pt) 2016-03-01
WO2010104761A3 (en) 2011-01-06
WO2010104761A2 (en) 2010-09-16
CN106432493B (zh) 2020-01-31
ES2584956T3 (es) 2016-09-30
US20220340670A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
JP6329842B2 (ja) 抗ｃｄ４０抗体及びその使用
JP6189379B2 (ja) 抗原提示細胞ターゲティングワクチン
US20210221904A1 (en) Fusion proteins comprising an anti-cd40 antibody and hiv antigenic peptides
HK1231897B (zh) 抗-cd40抗体及其用途
HK1227905B (zh) 靶向抗原呈递细胞的疫苗
HK1227048B (zh) 靶向抗原呈递细胞的癌症疫苗
HK1168117B (en) Anti-cd40 antibodies and uses thereof

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140310

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140801

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140919

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141119

R150 Certificate of patent or registration of utility model

Ref document number: 5653945

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250